Treatment of hepatitis C in coinfected patients

HCV and liver disease have emerged as major causes of morbidity and mortality in HIV-positive patients. Treating HCV in patients with HIV has been challenging up until a few years ago due to poorer outcomes with interferon-based therapies in this population. The direct-acting antiviral (DAA) agents...

Full description

Saved in:
Bibliographic Details
Published inFuture virology Vol. 10; no. 12; pp. 1291 - 1305
Main Authors Bello, David Del, Ita-Nagy, Fanny, Hand, Jonathan, Dieterich, Douglas
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.12.2015
Subjects
Antiretroviral therapy
Ascites
Clinical trials
coinfection
direct-acting antivirals
Drug use
Epidemiology
Hepatitis C
Hepatitis C virus
HIV
Human immunodeficiency virus
Infections
Interferon
Laboratories
Liver diseases
Morbidity
Mortality
Patients
Surveillance
Ultrasonic transducers
Womens health
United States > US
Online AccessGet full text

Cover

More Information
Summary:HCV and liver disease have emerged as major causes of morbidity and mortality in HIV-positive patients. Treating HCV in patients with HIV has been challenging up until a few years ago due to poorer outcomes with interferon-based therapies in this population. The direct-acting antiviral (DAA) agents offer a new era in the treatment of HCV for all patients regardless of HIV status. This article reviews multiple aspects of the care of the coinfected patient with a focus on the modern DAA agents. HCV clinical treatment trials involving HIV-positive patients and antiretroviral therapy/DAA drug-drug interactions are reviewed in detail.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1746-0794
1746-0808
DOI:10.2217/fvl.15.99